Thermo Fisher Scientific Inc. $TMO Shares Purchased by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 127.2% in the 4th quarter, Holdings Channel reports. The fund owned 3,628 shares of the medical research company’s stock after acquiring an additional 2,031 shares during the period. Soltis Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $2,102,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Howard Capital Management Inc. grew its stake in shares of Thermo Fisher Scientific by 0.5% during the fourth quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock valued at $1,791,000 after acquiring an additional 16 shares in the last quarter. Petros Family Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 3.9% during the fourth quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company’s stock valued at $264,000 after acquiring an additional 17 shares in the last quarter. Salomon & Ludwin LLC grew its stake in shares of Thermo Fisher Scientific by 1.6% during the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock valued at $669,000 after acquiring an additional 17 shares in the last quarter. Financial Management Network Inc. grew its stake in shares of Thermo Fisher Scientific by 3.7% during the third quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock valued at $248,000 after acquiring an additional 18 shares in the last quarter. Finally, Pallas Capital Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 1.5% during the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock valued at $728,000 after acquiring an additional 18 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMO has been the subject of several recent analyst reports. Barclays lowered their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. UBS Group reiterated a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Morgan Stanley reiterated an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Royal Bank Of Canada set a $490.00 price target on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $616.10.

Thermo Fisher Scientific Stock Down 0.0%

NYSE:TMO opened at $438.16 on Monday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The stock has a 50-day simple moving average of $486.00 and a 200 day simple moving average of $541.96. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a market capitalization of $162.83 billion, a price-to-earnings ratio of 24.09, a price-to-earnings-growth ratio of 1.94 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter last year, the company posted $5.15 earnings per share. Thermo Fisher Scientific’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were issued a $0.47 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.